SANUWAVE withdrew fiscal 2026 guidance due to Medicare reimbursement uncertainty.
Company will not provide guidance until after CMS issues final reimbursement rule, expected Q4 2026.
Overview
U.S. wound care device maker's Q2 revenue fell 3% yr/yr as system sales declined.
Gross margin dropped to 76.2% from 78.1% a year earlier.
Company withdrew 2026 guidance amid Medicare reimbursement uncertainty.
Key details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
$9.7 mln
Q2 Net Loss
$682,000
Q2 Gross Margin
76.2%
Q2 Operating Income
-$280,000
Result drivers
System sales decline - Company said ongoing stress in the customer base from CMS reimbursement changes and growth in the used system market hurt new system sales.
Applicator sales growth - Ultramist applicator revenue rose 13% yr/yr, making up about 75% of Q2 revenue.
SNWV•
